COVID-19: Remdesivir has “little or no effect” on mortality

Geneva | The antiviral drug Remdesivir, considered one of the most promising treatments for COVID-19, is not effective in preventing the death of patients, according to a study conducted with the support of the WHO.

• Read also: All developments in the COVID-19 pandemic

The drug “seems to have little or no effect on patients hospitalized for COVID-19, if we are to believe the mortality rates, the onset of ventilation or the length of hospitalization”, explains the study made public Thursday on the internet.

Remdesivir, which was part of the experimental treatment administered to US President Donald Trump when he was struck down by the disease in late September, is one of the drugs reviewed by this study, which involved more than 11,000 people in 30 countries. .

This study, which has yet to be reviewed by other doctors before its possible publication in a scientific journal, seems to contradict the last two large American studies which showed that Remdesivir could reduce the length of hospital stay.

Washington authorized on May 1 the use of this drug, manufactured by the American pharmaceutical company Gilead Sciences and originally intended as a treatment against the Ebola virus. The European Union and other countries then authorized it in turn.

About Victoria Smith

Victoria Smith who hails from Toronto, Canada currently runs this news portofolio who completed Masters in Political science from University of Toronto. She started her career with BBC then relocated to TorontoStar as senior political reporter. She is caring and hardworking.

Check Also

COVID-19: a party leads to the temporary closure of a high school in Trois-Rivières

The outbreak that has been raging since the end of September at Séminaire Saint-Joseph, in …

Leave a Reply

Your email address will not be published. Required fields are marked *